VANCOUVER, June 13 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation a medical technology company focused on photodisinfection technology, today announced that its Chief Technology Officer, Dr. Nicolas Loebel, is scheduled to present an overview of the Company’s operations including a discussion on its Periowave photodisinfection system at the Needham & Company, LLC Sixth Annual Biotechnology and Medical Technology Conference. The presentation is scheduled for 2:30 PM Eastern Time on Thursday June 14, 2007 at the New York Palace Hotel in New York City.
Interested parties may access the live webcast by visiting the Company’s website at www.ondinebiopharma.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio and slide arachive of the presentation will be available for approximately 90 days.
About Periowave(TM) and Photodisinfection
Periowave(TM) is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business PLC, University College London. Additional information about Periowave(TM) is available at www.periowave.com.
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.
The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company’s website at: www.ondinebiopharma.com.
Forward-Looking Statements:
Certain statements contained in this release containing words like “believe”, “intend”, “may”, “expect” and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company’s forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company’s filings.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release
Ondine Biopharma Corporation
CONTACT: Carolyn Cross, President and Chief Executive Officer, OndineBiopharma Corporation, (604) 669-0555, ccross@ondinebiopharma.com;Christina Bessant, Investor Relations, The Equicom Group Inc., (416)815-0700 ext. 269, cbessant@equicomgroup.com
